Palo Alto Investors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Palo Alto Investors’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,137	Closed	-$5K	–	39
2019 Q4	$5K	Hold	10,137	–	–	﹤0.01%	37
2019 Q3	$39K	Hold	10,137	–	–	﹤0.01%	37
2019 Q2	$67K	Hold	10,137	–	–	﹤0.01%	38
2019 Q1	$36K	Sell	10,137 -1	-0%	-$5	﹤0.01%	36
2018 Q4	$40K	Hold	10,138	–	–	﹤0.01%	35
2018 Q3	$200K	Hold	10,138	–	–	0.01%	35
2018 Q2	$322K	Hold	10,138	–	–	0.01%	36
2018 Q1	$375K	Hold	10,138	–	–	0.02%	36
2017 Q4	$801K	Buy	+10,138	New	+$750K	0.03%	34

Palo Alto Investors's MLNT Position: Q1 2020 in Review

Palo Alto Investors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 10,137 shares — an estimated $5K sold.

Palo Alto Investors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $801K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Palo Alto Investors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Palo Alto Investors sold 10,137 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $5K.
Palo Alto Investors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Palo Alto Investors's Melinta Therapeutics, Inc. Common Stock position peaked at $801K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Palo Alto Investors's 13F filing for Q1 2020, filed 15 May 2020.